Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 246

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The FDA-approved drug sofosbuvir inhibits Zika virus infection

Open access
Bullard-Feibelman, Kristen M., Govero, Jennifer, Zhu, Zhe, Salazar, Vanessa, Veselinovic, Milena, Diamond, Michael S., Geiss, Brian J.·2017·Antiviral Research

Abstract

&NA; The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with severe cases causing Guillain‐Barré syndrome, congenital malformations, and microcephaly. Currently, there is no available vaccine or therapy to prevent or treat ZIKV infection. We evaluated whether sofosbuvir, an FDA‐approved nucleotide polymerase inhibitor for the distantly related hepatitis C virus, could have antiviral activity against ZIKV infection. Cell culture studies established that sofosbuvir efficiently inhibits replication and infection of several ZIKV strains in multiple human tumor cell lines and isolated human fetal‐derived neuronal stem cells. Moreover, oral treatment with sofosbuvir protected against ZIKV‐induced death in mice. These results suggest that sofosbuvir may be a candidate for further evaluation as a therapy against ZIKV infection in humans. HighlightsSofosbuvir reduces replication of multiple ZIKV isolates in human liver and placental cells.Sofosbuvir protects human neuronal stem cells from ZIKV infection.Oral administration of sofosbuvir via drinking reduces ZIKV death in mice.Sofosbuvir should be evaluated as an anti‐ZIKV treatment in non‐rodent species.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.antiviral.2016.11.023

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 246

Metadata

Authors
Bullard-Feibelman, K. M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M. S., & Geiss, B. J.
Venue
Antiviral Research
Publisher
Elsevier BV
Published
2017-01
Volume
137
Pages
134-140
ISSN
0166-3542 (ISSN-L)
OpenAlex
W2552845139
Cited by
246
References
3
FWCI
36.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The FDA-approved drug sofosbuvir inhibits Zika virus infection. https://app.cochat.ai/papers/10.1016/j.antiviral.2016.11.023
The paper
Bullard-Feibelman, K. M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M. S., & Geiss, B. J. (2017). The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Research. https://doi.org/10.1016/j.antiviral.2016.11.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.